Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: Results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles - 24/04/13
, William Abramovits, MD b, Brian Berman, MD c, James Kulp, BS d, Darrell S. Rigel, MD e, Sharon Levy, MD d
Reprint requests: Neil Swanson, MD, Department of Dermatology, Oregon Health and Science University, Center for Health and Healing, 3303 SW Bond Ave, Portland, OR 97239.Abstract |
Background |
The approved imiquimod 5% cream regimen for treating actinic keratoses requires a long treatment time and is limited to a small area of skin.
Objective |
We sought to evaluate imiquimod 2.5% and 3.75% for short-course treatment of the full face or balding scalp.
Methods |
In two identical studies, adults with 5 to 20 lesions were randomized to placebo, imiquimod 2.5%, or imiquimod 3.75% (1:1:1). Up to two packets (250 mg each) were applied per dose once daily for two 2-week treatment cycles, with a 2-week, no-treatment interval between cycles. Efficacy was assessed at 8 weeks posttreatment.
Results |
A total of 479 patients were randomized to placebo, or imiquimod 2.5% or 3.75%. Complete and partial clearance (≥75% lesion reduction) rates were 6.3% and 22.6% for placebo, 30.6% and 48.1% for imiquimod 2.5%, and 35.6% and 59.4% for imiquimod 3.75%, respectively (P < .001 vs placebo, each; P = .047, 3.75% vs 2.5% for partial clearance). Median reductions from baseline in lesion counts were 25.0% for placebo, 71.8% for imiquimod 2.5%, and 81.8% for imiquimod 3.75% (P < .001, each active vs placebo; P = .048 3.75% vs 2.5%). There were few treatment-related discontinuations. Patient rest period rates were 0% for placebo, 6.9% for imiquimod 2.5%, and 10.6% for imiquimod 3.75%.
Limitations |
Local pharmacologic effects of imiquimod, including erythema, may have limited concealment of treatment assignment in some patients.
Conclusions |
Both imiquimod 2.5% and 3.75% creams were more effective than placebo and were well tolerated when administered daily as a 2-week on/off/on regimen to treat actinic keratoses.
Le texte complet de cet article est disponible en PDF.Key words : actinic keratosis, clinical trial, dose optimization, imiquimod
Abbreviations used : AE, AK, ASR, EOS, IGIP, LSR
Plan
| Funding sources: Graceway Pharmaceuticals LLC. |
|
| Disclosure: Dr Swanson was an investigator and consultant for Graceway, and has received compensation for services. Dr Abramovits was an investigator and speaker for Graceway and has received compensation for services. Dr Berman was an advisory board member and speaker for Graceway and has received compensation for services. Mr Kulp and Dr Levy are employees of Graceway. Dr Rigel was a consultant, advisory board member, and investigator for Graceway and has received compensation for services. |
Vol 62 - N° 4
P. 582-590 - avril 2010 Retour au numéro
Article précédent
- Volunteers Needed
- Low rates of clinical recurrence after biopsy of benign to moderately dysplastic melanocytic nevi
- Agnessa Gadeliya Goodson, Scott R. Florell, Kenneth M. Boucher, Douglas Grossman
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?